CCCC - Company ID 0001662579
The table below shows C4 Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$98.69M | -$65.16M | -$106.84M | -$105.94M | -$86.97M | -$67.25M |
| Capital expenditure | $607.00K | $180.00K | $1.71M | $5.50M | $1.28M | $650.00K |
| Investing cash flow | -$8.60M | -$51.27M | $158.35M | $58.42M | -$189.34M | -$190.50M |
| Dividends paid | - | - | - | - |
C4 Therapeutics, Inc. reported operating cash flow of -$98.69M for fiscal year 2025. That is down 51.5% from -$65.16M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $55.61M (FY 2019) to -$98.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | $193.00K | $194.00K | $110.00K | $0.00 | - | $194.00K |
| Financing cash flow | $126.40M | $45.34M | $45.49M | $1.15M | $171.40M | $348.93M |